Menu Search
Equities

Biogen Inc

IDP:STU

Biogen Inc

Actions
  • Price (EUR)139.00
  • Today's Change-1.30 / -0.93%
  • Shares traded134.00
  • 1 Year change-32.26%
  • Beta--
Data delayed at least 15 minutes, as of Mar 10 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

  • Revenue in USD (TTM)9.68bn
  • Net income in USD1.63bn
  • Incorporated1997
  • Employees7.61k
  • Location
    Biogen Inc225 Binney StreetCAMBRIDGE 02142United StatesUSA
  • Phone+1 (781) 464-2000
  • Fax+1 (302) 636-5454
  • Websitehttps://www.biogen.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BIIB:NSQ since
announced		Transaction
value
Sage Therapeutics IncAnnounced10 Jan 202510 Jan 2025Announced-0.03%396.61m
Human Immunology Biosciences IncDeal completed22 May 202422 May 2024Deal completed-33.81%1.80bn
Data delayed at least 15 minutes, as of Mar 10 2025 20:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.